Stock 2186 LUYE PHARMA GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:35 2024-04-19 am EDT 		5-day change 1st Jan Change
2.61 HKD -0.38% Intraday chart for Luye Pharma Group Ltd. -7.77% -30.03%
Mar. 27 Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 07 Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI

Business Summary

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.

Number of employees: 5,005

Sales per Business

HKD in Million2021Weight2022Weight Delta
Oncology Drugs
38.5 %
1,704 27.2 % 2,681 38.5 % +57.33%
Cardiovascular System Drugs
25.7 %
1,720 27.4 % 1,786 25.7 % +3.82%
Central Nervous System Drugs
22.1 %
1,595 25.5 % 1,538 22.1 % -3.59%
Alimentary Tract and Metabolism Drugs
10.6 %
1,083 17.3 % 735 10.6 % -32.09%
Others
3.1 %
165 2.6 % 215 3.1 % +30.68%

Sales per region

HKD in Million2021Weight2022Weight Delta
China
84.1 %
5,107 81.5 % 5,851 84.1 % +14.56%
Asia (other than China)
5.7 %
535 8.5 % 398 5.7 % -25.55%
European Union
5.2 %
294 4.7 % 360 5.2 % +22.22%
Other Countries
5.0 %
331 5.3 % 348 5.0 % +4.94%

Managers

Managers TitleAgeSince
Dian Bo Liu CEO
 Chief Executive Officer 59 03-07-01
Rong Bing Yang PSD
 President 58 94-06-07
Yun Li Xue PRN
 Corporate Officer/Principal 60 94-06-07
Mei Yi Lee SEC
 Corporate Secretary 56 20-11-30

Members of the board

Members of the board TitleAgeSince
Hui Xian Yuan BRD
 Director/Board Member 65 94-06-07
Rong Bing Yang PSD
 President 58 94-06-07
Dian Bo Liu CEO
 Chief Executive Officer 59 03-07-01
Hua Qiao Zhang BRD
 Director/Board Member 61 14-05-31
Man Kit Leung BRD
 Director/Board Member 71 14-05-31
Yuk Lam Lo BRD
 Director/Board Member 76 14-05-31
Sze Chung Choy BRD
 Director/Board Member 65 14-05-31
Rui Lin Song BRD
 Director/Board Member 61 17-03-28
Yuan Yuan Zhu BRD
 Director/Board Member 43 09-07-31
Dong Lyu BRD
 Director/Board Member 49 Dec. 05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,549,670,643 1,950,149,832 ( 54.94 %) 0 54.94 %

Shareholders

NameEquities%Valuation
Dian Bo Liu
33.47 %
1,259,196,703 33.47 % 439 M $
Hillhouse Investment Management Ltd. (Invest)
14.68 %
552,324,108 14.68 % 193 M $
E Fund Management Co., Ltd.
4.912 %
184,787,500 4.912 % 64 M $
UBS Asset Management Switzerland AG
3.904 %
146,868,477 3.904 % 51 M $
New Leaf Venture Partners LLC
2.636 %
99,154,285 2.636 % 35 M $
Zhong Geng Fund Management Co. , Ltd.
1.642 %
61,760,500 1.642 % 22 M $
China Southern Asset Management Co., Ltd.
0.5693 %
21,415,000 0.5693 % 7 M $
Bosera Asset Management Co., Ltd.
0.4782 %
17,989,000 0.4782 % 6 M $
GF Fund Management Co., Ltd.
0.2207 %
8,301,500 0.2207 % 3 M $
China Asset Management Co., Ltd.
0.1454 %
5,471,000 0.1454 % 2 M $

Holdings

NameEquities%Valuation
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
70.81%
 360,596,456 70.81% 465,349,726 $

Company contact information

Luye Pharma Group Ltd.

No. 15 Chuang Ye Road High-Tech Industrial Development Zon

264003, Yantai

+

http://www.luye.cn
address Luye Pharma Group Ltd.(2186)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Luye Pharma Group Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
2.422 CNY
Average target price
2.775 CNY
Spread / Average Target
+14.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LUYE PHARMA GROUP LTD. Stock Luye Pharma Group Ltd.
-30.29% 1.26B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.82% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.81% 211B
NOVARTIS AG Stock Novartis AG
-0.70% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-10.14% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 2186 Stock
  4. Company Luye Pharma Group Ltd.